Next Article in Journal
Glass Formation, Chemical Properties and Surface Analysis of Cu-Based Bulk Metallic Glasses
Next Article in Special Issue
Sulfotyrosine Recognition as Marker for Druggable Sites in the Extracellular Space
Previous Article in Journal
Improving the Accuracy of Density Functional Theory (DFT) Calculation for Homolysis Bond Dissociation Energies of Y-NO Bond: Generalized Regression Neural Network Based on Grey Relational Analysis and Principal Component Analysis
Previous Article in Special Issue
Application of Molecular Topology for the Prediction of Reaction Yields and Anti-Inflammatory Activity of Heterocyclic Amidine Derivatives
Article Menu

Export Article

Open AccessReview
Int. J. Mol. Sci. 2011, 12(4), 2262-2274; doi:10.3390/ijms12042262

Multi-Step Usage of in Vivo Models During Rational Drug Design and Discovery

Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
Research Medicine, Veterans Affairs TVHS, Nashville, TN 37212, USA
Author to whom correspondence should be addressed.
Received: 1 March 2011 / Revised: 25 March 2011 / Accepted: 29 March 2011 / Published: 1 April 2011
(This article belongs to the Special Issue A Systematic Development Method for Rational Drug Design)
View Full-Text   |   Download PDF [305 KB, uploaded 19 June 2014]   |  


In this article we propose a systematic development method for rational drug design while reviewing paradigms in industry, emerging techniques and technologies in the field. Although the process of drug development today has been accelerated by emergence of computational methodologies, it is a herculean challenge requiring exorbitant resources; and often fails to yield clinically viable results. The current paradigm of target based drug design is often misguided and tends to yield compounds that have poor absorption, distribution, metabolism, and excretion, toxicology (ADMET) properties. Therefore, an in vivo organism based approach allowing for a multidisciplinary inquiry into potent and selective molecules is an excellent place to begin rational drug design. We will review how organisms like the zebrafish and Caenorhabditis elegans can not only be starting points, but can be used at various steps of the drug development process from target identification to pre-clinical trial models. This systems biology based approach paired with the power of computational biology; genetics and developmental biology provide a methodological framework to avoid the pitfalls of traditional target based drug design. View Full-Text
Keywords: phenotypic screen; drug discovery; small molecules; drug design chemical genetics; model organisms phenotypic screen; drug discovery; small molecules; drug design chemical genetics; model organisms

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Williams, C.H.; Hong, C.C. Multi-Step Usage of in Vivo Models During Rational Drug Design and Discovery. Int. J. Mol. Sci. 2011, 12, 2262-2274.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top